Gene screening and prevention of hereditary breast cancer: A clinical view

European Journal of Cancer, Supplement

Volumn 1, Issue 1, 2003, Pages 13-23

  Klijn, J G M ^a   Meijers Heijboer, H ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; DNA; TAMOXIFEN;

ADULT; ARTICLE; BREAST CARCINOMA; CANCER PREVENTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA DETERMINATION; FEMALE; GENETIC ANALYSIS; HUMAN; LIFESTYLE; MAJOR CLINICAL STUDY; MAMMOGRAPHY; MASTECTOMY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL;

EID: 2442475598     PISSN: 13596349     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6349(03)00005-3     Document Type: Article

References (99)

1. Harris J.R., Lippmann M.E., Veronesi U., Willett W. Breast Cancer (part 1). New Engl. J. Med. 327:1992;319-328
2. Klijn J.G.M., Berns P.M.J.J., Foekens J.A. Prognostic and predictive factors and targets for therapy in breast cancer. Pasqualini J.R. Breast Cancer: Prognosis, Treatment and Prevention. 2002;93-124 Marcel Dekker, New York
3. Olopade O.I., Fackenthal J.D. Breast cancer genetics, implications for clinical practice. Hematol/Oncol Clin North Am. 14:2000;705-725
4. Verhoog L.C., van den Ouweland A.M.W., Berns P.M.J.J., et al. Large regional differences in the frequency of distinct BRCA1/BRCA2 mutations in 517 Dutch breast and/or ovarian cancer families. Eur. J. Cancer. 37:2001;2082-2090
5. Lichtenstein P., Holm N.V., Verkasalo P.K., et al. Environmental and heritable factors in the causation of cancer. N. Engl. J. Med. 343:2000;78-85
6. Miki Y., Swensen J., Shattuck-Eidens D., et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 266:1994;66-71
7. Wooster R., Bignell G., Lancaster J., et al. Identification of the breast cancer susceptibility gene BRCA2. Nature. 378:1995;789-792. [erratum, Nature 1996;379:749]
8. Ford D., Easton D.F., Bishop D.T., et al. Risks of cancer in BRCA1 mutation carriers. Lancet. 343:1994;992-995
9. Easton DF, Ford D, Bishop DF and the Breast Cancer Linkage Consortium Breast and ovarian cancer incidence in BRCA1-mutations carriers. Am. J. Hum. Genet. 56:1995;265-271
10. Ford D., Easton D.F., Stratton M., et al. Genetic Heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am. J. Hum. Genet. 62:1998;676-689
11. Easton D.F., Steele L., Fields P., et al. Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12-13. Am. J. Hum. Genet. 61:1998;120-128
12. The Breast Cancer Linkage Consortium Cancer risks in BRCA2 mutation carriers. J. Natl. Cancer Inst. 91:1999;1310-1316
13. Devilee P. BRCA1 and BRCA2 testing. weighing the demand against the benefits Am. J. Hum. Genet. 64:1999;943-948
14. Thompson D., Szabo C., Mangion J., et al. Evaluation of linkage of breast cancer to the putative BRCA3 locus on chromosome 13q21 in 128 multiple case families from the Breast Cancer Linkage Consortium. PNAS. 99:2002;827-831
15. Bilimoria M.M., Morrow M. The women at increased risk for breast cancer. evaluation and management strategies CA Cancer J. Clin. 45:1995;263-278
16. American Society of Clinical Oncology Statement of the American Society of Clinical Oncology. genetic testing for cancer susceptibility J. Clin. Oncol. 14:1996;1730-1736
17. Burke W., Daly M., Garber J., et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. JAMA. 77:1997;997-1003
18. Hall J.M., Lee M.K., Newman B., et al. Linkage of early onset familial breast cancer to chromosome 17q21. Science. 250:1990;1684-1689
19. Claus E.B., Schildkraut J.M., Thompson W.D., Risch N.J. The genetic attributable risk of breast and ovarian cancer. Cancer. 77:1996;2318-2324
20. Dupont W.D., Page D.L. Risk factors for breast cancer in women with proliferative disease. N. Engl. J. Med. 312:1985;146-151
21. Gail M.H., Brinton L.A., Byar D.P., et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J. Natl. Cancer Inst. 81:1989;1879-1886
22. Struewing J.P., Hartge P., Wacholder S., et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N. Eng. J. Med. 336:1997;1401-1408
23. Lakhani SR, Easton DF, Stratton MR and Breast Cancer Linkage Consortium Pathology of familial breast cancer. differences in carriers of BRCA1 or BRCA2 mutations and sporadic cases Lancet. 349:1997;4505-4510
24. Lakhani S.R., Jacquemier J., Sloane J.P., et al. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J. Natl. Cancer Inst. 90:1998;1138-1145
25. Lakhani S.R., Gusterson B.A., Jacquemier J., et al. The pathology of familial breast cancer. histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2 Clin. Cancer Res. 6:2000;782-789
26. Chang J., Elledge R.M. Clinical management of women with genomic BRCA1 and BRCA2 mutations. Breast Cancer Res. Treat. 69:2001;101-113
27. Phillips K.-A., Adrulis I.L., Goodwin P.J. Breast carcinomas arising in carriers of mutations in BRCA1 or BRCA2. are they prognostically different? J. Clin. Oncol. 17:1999;3653-3663
28. Verhoog L.C., Brekelmans C.T.M., Seynaeve C., et al. Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1. Lancet. 351:1998;316-321
29. Chappuis P.O., Rosenblatt J., Foulkes W.D. The influence of familial and hereditary factors on the prognosis of breast cancer. Ann. Oncol. 10:1999;1163-1170
30. Verhoog L.C., Brekelmans C.T.M., Seynaeve C., et al. Survival in hereditary hereditary breast cancer associated with germline mutations of BRCA2. J. Clin. Oncol. 17:1999;3396-3402
31. Verhoog L.C., Berns E.M.J.J., Brekelmans C.T.M., et al. Prognostic significance of germline BRCA2 mutations in hereditary breast cancer patients. J. Clin. Oncol. 18:2000;119s-124s
32. Verhoog L.C., Brekelmans C.T.M., Seynaeve C., Meijers-Heijboer E.J., Klijn J.G.M. Contralateral breast cnacer risk is influenced by the age at onset in BRCA1-associated breast cancer. Br. J. Cancer. 83:2000;384-386
33. Lerman C., Narod S., Shulman K., et al. BRCA1 testing in families with hereditary breast-ovarian cancer. a prospective study of patient decision making and outcomes JAMA. 275:1996;1885-1892
34. Lynch H.T., Lemon S.J., Durham C., et al. A descriptive study of BRCA1 testing and reactions to disclosure of test results. Cancer. 79:1997;2219-2228
35. Lynch H.T., Watson P., Tinley S., et al. An update on DNA-based BRCA1/BRCA2 genetic counseling in hereditary breast cancer. Cancer Genet. Cytogenet. 109:1999;91-98
36. Meijers-Heijboer E.J., Verhoog L.C., Brekelmans C.T.M., et al. Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation. Lancet. 355:2000;2015-2020
37. Lerman C., Seay J., Balshem A., Audrain J. Interest in genetic testing among first-degree relatives of breast cancer patients. Am. J. Med. Genet. 57:1995;385-392
38. Jacobsen P.B., Valdimarsdottir H.B., Brown K.L., Offit K. Decision-making about genetic testing among women at familial risk for breast cancer. Psychosom. Med. 59:1997;459-466
39. Hogervorst F.B.L., Cornelis R.S., Bout M., et al. Rapid detection of BRCA1 mutations by the protein truncation test. Nat. Genet. 10:1995;208-212
40. Petrij-Bosch A., Peelen T., van Vliet M., et al. BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients. Nat. Genet. 17:1997;341-345. [erratum, Nat Genet 1997;17:503]
41. Peelen T., van Vliet M., Petrij-Bosch A., et al. A high proportion of novel mutations in BRCA1 with strong founder effects among Dutch and Belgian hereditary breast and ovarian cancer families. Am. J. Hum. Genet. 60:1997;1041-1049
42. Peelen T., van Vliet M., Bosch A., et al. Screening for BRCA2 mutations in 81 Dutch breast-ovarian cancer families. Br. J. Cancer. 82:2000;151-156
43. Couch F.J., DeShano M.L., Blackwood M.A., et al. BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N. Engl. J. Med. 336:1997;1409-1415
44. Stoppa-Lyonnet D., Laurent-Puig P., Essioux L., et al. BRCA1 sequence variations in 160 individuals referred to a breast/ovarian family cancer clinic. Am. J. Hum. Genet. 60:1997;1021-1030
45. Shattuck-Eidens C., Oliphant A., McClure M., et al. BRCA1 sequence analysis in women at high risk for susceptibility mutations; risk factor analysis and implications for genetic testing. JAMA. 278:1997;1242-1250
46. Frank T.S., Manley S.A., Olopade O.I., et al. Sequence analysis of BRCA1 and BRCA2. correlation of mutations with family history and ovarian cancer risk J. Clin. Oncol. 16:1998;2417-2425
47. Ligtenberg M.J.L., Hogervorst F.B.L., Willems H.W., et al. Characteristics of small breast and/or ovarian cancer families with germline mutations in BRCA1 and BRCA2. Br. J. Cancer. 79:1999;1475-1478
48. Shih H.A., Couch F.J., Nathanson K.L., et al. BRCA1 and BRCA2 mutation frequency in women evaluated in a breast cancer risk evaluation clinic. J. Clin. Oncol. 20:2002;994-999
49. Szabo C.I., King M.C. Population genetics of BRCA1 and BRCA2. Am. J. Hum. Genet. 60:1997;1013-1020
50. Neuhausen S.L. Ethnic differences in cancer risk resulting from genetic variation. Cancer. 86:1999;2575-2582
51. Pisano M., Cossu A., Persico I., et al. Identification of a founder BRCA2 mutation in Sardinia. Br. J. Cancer. 82:2000;553-559
52. Sarantaus L., Huusko P., Eerola H., et al. Multiple founder effects and geographical clustering of BRCA1 and BRCA2 families in Finland. Eur. J. Hum. Genet. 8:2000;757-763
53. Gorski B., Byrski T., Huzarski T., et al. Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer. Am. J. Hum. Genet. 66:2000;1963-1968
54. Klijn J.G.M., Janin N., Cortes-Funes H., Colomer R. Should prophylactic surgery be used in women with a high risk of breast cancer? Eur. J. Cancer. 33:1997;2149-2159
55. Chlebowski R.T. Reducing the risk of breast cancer. N. Eng. J. Med. 343:2000;191-198
56. Salih A.K., Fentiman I.S. Breast cancer prevention. present and future Cancer Treat. Rev. 27:2001;161-173
57. Narod S.A., Risch H., Moslehi R., et al. Oral contraceptives and the risk of hereditary ovarian cancer. N. Engl. J. Med. 339:1998;424-428
58. Narod S.A., Dubé M.-P., Klijn J.G.M., et al. Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J. Natl. Cancer Inst. 94:2002;1773-1779
59. Olsen O., Götzsche P.C. Cochrane review on screening for breast cancer with mammography. Lancet. 358:2001;1340-1342
60. Nyström L., Andersson I., Bjurstam N., Frisell J., Nordenskjöld B., Rutqvist L.E. Long-term effects of mammography screening. updated overview of the Swedish randomised trials Lancet. 359:2002;909-919
61. Report of the Organizing Committee and Collaborators, Falun Meeting, Sweden (21 and 22 March 1996): breast-cancer screening with mammography in women aged 40-49 years. Int J Cancer 1996, 68, 693-699.
62. Elmore J.G., Barton M.B., Moceri V.M., et al. Ten-year risk of false positive screening mammograms and clinical breast examinations. N. Eng. J. Med. 338:1998;1089-1096
63. Kerlikowske K., Grady D., Barclay J., et al. Effect of age, breast density and family history on the sensitivity of first screening mammography. JAMA. 276:1996;33-38
64. Brekelmans C.T.M., Seynaeve C., Bartels C.C.M., et al. Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk. J. Clin. Oncol. 19:2001;924-930
65. Vasen H.F.A., Haites N.E., Evans D.G.R., et al. Current policies for surveillance and management in women at risk of breast and ovarian cancer. a survey among 16 European Family Cancer Clinics Eur. J. Cancer. 34:1998;1922-1926
66. Kuhl C.K., Schmutzler R.K., Leutner C., et al. Breast MR imaging screening in 192 women proved or suspected to be carriers of a breast cancer susceptibility gene. preliminary results Radiology. 215:2000;267-279
67. Kriege M., Brekelmans C.T.M., Boetes C., et al. MRI screening for breast cancer in women with familial or genetic predisposition. design of the Dutch National Study (MRISC) Famil Cancer. 1:2001;163-168
68. Meijers-Heijboer H., van Geel A.N., van Putten W.L.J., et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N. Engl. J. Med. 345:2001;159-164
69. Stoutjesdijk M.J., Boetes C., Jager G.J., et al. Magnetic resonance imaging and mammogaphy in women with a hereditary risk of breast cancer. J. Natl. Cancer Inst. 93:2001;1095-1102
70. Warner E., Plewes D.B., Shumak R.S., et al. Comparison of breast magnetic resonance imaging, mammography, and ultrasound for surveillance of women at high risk for hereditary breast cancer. J. Clin. Oncol. 19:2001;3524-3531
71. Lodder L.N., Frets P.G., Trijsburg R.W., et al. One year follow-up of women opting for presymptomatic testing for BRCA1 and BRCA2. emotional impact of the test outcome and decisions on risk management (surveillance or prophylactic surgery) Breast Cancer Res. Treat. 73:2002;97-112
72. Shrag D., Kuntz K.M., Garber J.E., et al. Decision analysis-effects of prophylactic mastectomy and oophorectomy on life expectancy among young women with BRCA1 or BRCA2 mutations. New Eng. J. Med. 336:1997;1465-1471
73. Meijers-Heijboer EJ, Brekelmans CTM, Menke-Pluymers M, et al. Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast and/or ovarian cancer from families with a BRCA1 or BRCA2 mutation. J Clin Oncol. 21:2003;1675-1681
74. Eisen A., Rebbeck T.R., Wood W.C., Weber B.L. Prophylactic surgery in women with a hereditary predisposition to breast and ovarian cancer. J. Clin. Oncol. 18:2000;1980-1995
75. Stefanek M., Hartmann L., Nelson W. Risk-reduction mastectomy. clinical issues and research needs J. Natl. Cancer Inst. 93:2001;1297-1306
76. Lynch H.T., Lynch J.F., Rubinstein W.S. Prophylactic mastectomy. obstacles and benefits J. Natl. Cancer Inst. 93:2001;1586-1587
77. Hartmann L.C., Schaid D.J., Woods J.E., et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N. Engl. J. Med. 340:1999;77-84
78. Hartmann L.C., Sellers T.A., Schaid D.J., et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J. Natl. Cancer Inst. 93:2001;1633-1637
79. Khurana K.K., Loosmann A., Numann P.J., Khan S.A. Prophylactic mastectomy. pathologic findings in high-risk patients Arch. Pathol. Lab. Med. 124:2000;378-381
80. Skolnick M.H., Cannon-Albright L.A., Goldgar D.E., et al. Inheritance of proliferative breast disease in breast cancer kindreds. Science. 250:1990;1715-1720
81. Eisen A., Weber B.L. Prophylactic mastectomy - the price of fear. N Eng. J. Med. 340:1999;137-138
82. Eisinger F., Geller G., Burke W., Holtzman N.A. Cultural basis for differences between US and French clinical recommendations for women at increased risk of breast and ovarian caner. Lancet. 353:1999;919-920
83. Evans D.G.R., Lalloo F., Shenton A., Boggis C., Howell A. Uptake of screening and prevention in women at very high risk of breast cancer. Lancet. 358:2001;889-890
84. Gabriel S.E., Woods J.E., O'Fallon W.M., Beard C.M., Kurland L.T., Melton III L.J. Complications leading to surgery after breast implantation. N. Engl. J. Med. 336:1997;677-682
85. Zion S.M., Slezak J.M., Schaid D.J., et al. Surgical morbidities following bilateral prophylactic mastectomy. Prog. Proc. Am. Soc. Clin. Oncol. 19:2000;441a. (abstr)
86. Contant C.M.E., Menke-Pluymers M.B.E., Seynaeve C., et al. Clinical experience of prophylactic mastectomy followed by immediate breast reconstruction in women at hereditary risk of breast cancer (HB(O)C) or a proven BRCA1 and BRCA2 germ-line mutation. Eur. J. Surg. Oncol. 28:2002;627-632
87. Stefanek M.E., Helzlsouer K.J., Wilcox P.M., Houn F. Predictors of and satisfaction with bilateral prophylactic mastectomy. Prev. Med. 24:1995;412-419
88. Borgen P.I., Hill A.D.K., Tran K.N., et al. Patient regrets after bilateral prophylactic mastectomy. Ann. Surg. Oncol. 5:1998;603-606
89. Frost M.H., Schaid D.J., Sellers T.A., et al. Long-term satisfaction and psychological and social function following bilateral prophylactic mastectomy. JAMA. 284:2000;319-324
90. Hatcher M.B., Fallowfield L., A'Hern R. The psychosocial impact of bilateral prophylactic mastectomy. prospective study using questionnaires and semistructured interviews Br. Med. J. 322:2001;1-7
91. O'Regan R.M., Jordan V.C. Tamoxifen to raloxifen and beyond. Sem. Oncol. 28:2001;260-273
92. Kauff N.D., Satagopan J.M., Scheuer L., et al. Salpingo-Oophorectomy in women with BRCA1 and BRCA2 mutations. N. Engl. J. Med. 346:2002;1609-1615
93. Rebbeck T.R., Levin A.M., Eisen A., et al. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J. Natl. Cancer Inst. 91:1999;1475-1479
94. Rebbeck T.R., Lynch H.T., Neuhausen S.L., et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N. Engl. J. Med. 346:2002;1616-1622
95. Narod S.A., Brunet J.-S., Ghadirian P., et al. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. a casecontrol study Lancet. 356:2000;1876-1881
96. Fisher B., Costantino J.P., Wickerham D.L., et al. Tamoxifen for prevention of breast cancer. report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study J. Natl. Cancer Inst. 90:1998;1371-1388
97. IBIS I. first results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet 2002, 360, 817-824.
98. Powles T., Eeles R., Ashley S., et al. Interim analysis of the incidence of breaast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet. 352:1998;98-101
99. King M.-C., Wieand S., Hale K., et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2. NSABP-P1 breast cancer prevention trial JAMA. 286:2001;2251-2256